جستجوی مقالات مرتبط با کلیدواژه « Post-COVID-19 » در نشریات گروه « پزشکی »

This study aims to identify the outcomes of healthy lifestyles during the post-COVID-19 era in the Iranian health system.

A qualitative field study was conducted based on the interpretive paradigm and inductive reasoning using theoretical and non-probability sampling techniques. Our study adopted the grounded theory approach, and semi-structured interviews were employed as data collection tools. While theoretical saturation was reached by the end of the thirteenth interview, the interviews continued until the fifteenth interview for further certainty. Faculty members and experts with doctoral degrees at Mashhad University of Medical Sciences constituted the statistical population from whom 15 individuals were recruited based on inclusion and exclusion criteria. The hidden content of interviews was summarized, coded, and analyzed using the MAXQDA software.

The researcher and supervising professors extracted 37 initial concepts, of which six remained after eliminating duplicates. The outcomes of healthy lifestyles during the post-COVID-19 era emerged from the intuitive opinions of experts, namely, the promotion of social capital, the promotion of psychological capital, and the movement toward development.

The research findings led to the identification of the outcomes of healthy lifestyles during the post-coronavirus era.

The COVID-19 pandemic has been unresolved for 3 years. Numerous individuals have survived COVID-19 but suffered from a variety of problems or symptoms for several months. This report presents our experience regarding a post–COVID-19 patient with exacerbated symptoms of congestive heart failure and congestive hepatopathy.

Two months after being diagnosed with COVID-19, a 47-year-old man presented to Universitas Islam Indonesia Hospital with significant shortness of breath and abdominal enlargement. Cardiomegaly, increased jugular venous pressure, hepatomegaly, ascites, and bilateral edema of the legs were all indicators of congestive heart failure. Cardiomegaly was discovered on a chest X-ray. Electrocardiography revealed ischemic heart illness with an old myocardial infarction. Aspartate transaminase (911 U/L), alanine transaminase (820 U/L), and total bilirubin (4-6 mg/dL) were increased. Ultrasonography of the abdomen demonstrated congestive hepatopathy with ascites. Echocardiography showed hypokinetic cardiac wall movements and a 21% decrease in the ejection fraction. He had a comorbidity of uncontrolled diabetes mellitus. The symptoms subsided after therapy with furosemide, spironolactone, dobutamine, nebivolol, sacubitril, valsartan, L-ornithine-L-aspartate, insulin, and a broad spectrum of antibiotics. After 10 days of hospitalization with comprehensive management, the patient’s condition improved.

Our post–COVID-19 patient suffering from congestive heart failure with a poor ejection fraction and severe congestive hepatopathy had an improved outcome following our comprehensive management. (Iranian Heart Journal 2023; 24(3): 100-107)

This study was designed to differentiate between the impact of the topical nasal spray of corticosteroids, antihistamines, a combination of them, and normal 0.2% saline in treating patients with post-coronavirus disease 2019 (COVID-19) smell dysfunction.

Patients with hyposmia or anosmia (n = 240), who recently recovered from COVID-19, were enrolled in this trial and were randomly assigned to four parallel groups. Group I (G1) received a combination of topical corticosteroid and antihistamine nasal spray (n = 60). Group II (G2) received topical corticosteroid nasal spray (n = 60). Group III (G3) received antihistamine nasal spray (n = 60). Group IV (G4) received 0.2% normal nasal saline nasal spray (n = 60). The treatments were used in all groups for 3 weeks. The sense of smell was assessed using the butanol threshold and discrimination tests. The smell tests were evaluated weekly for 3 weeks.

The mean age of the patients was 51.9 ± 7.1 years; moreover, 83.8% and 16.3% were male and female, respectively. The results of the smell tests in the first week significantly improved with those in the third week (P< 0.001). The greatest degree of improvement was found in the first group, followed by the second, third, and fourth groups.

The results suggest the ability of combination therapy of corticosteroid and antihistamine nasal spray to manage post-COVID-19 hyposmia or anosmia; however, this combination therapy was not superior to corticosteroid nasal spray. 

COVID-19 infection causes a wide spectrum of macrovascular thrombosis, which has contributed significantly tomorbidity and mortality in the elderly. Guidelines have recommended extended prophylaxis following discharge from the hospital for variable periods. The risk of thrombosis and the optimal duration of extended anticoagulation remain uncertain.

This study aimed at determining the overall incidence and timing of macrovascular thrombosis in post-COVID-19 elderly patients. It also aimed at finding out the predictive value of clinical severity, in-hospital anticoagulation, and discharge Ddimer values for the incidence of macrovascular thrombosis and overall mortality within 13 weeks following clinical recovery from acute COVID-19 infection in the elderly.

In this study, 288 elderly patients with symptomatic acute COVID-19 infection discharged between August 1, 2020, and November 30, 2020, were enrolled. Details regarding the incidence of macrovascular thrombosis were collected through a telephone interview after 90 days. Data were tabulated and analyzed with IBM SPSS Statistics for Windows, Version 23.0. (Armonk, NY: IBM Corp.)

The number of macrovascular thrombotic events was significantly higher in group C (critical illness) than in the other two groups (17.9 vs. 1.8 and 1.1%, respectively) (P = 0.0005). Three (10.7%) patients died within 13 weeks of discharge in group C, versus one (0.6%) patient in group M (mild to moderate illness) and none in group S (severe illness) (P = 0.0005). There were two macrovascular thrombotic events in the elevated D-dimer group versus one in the reduced D-dimer group (P = 0.135). The number of deaths was high in the elevated D-dimer group [2 (8.3%) vs. 0 (0), P = 0.053]. The cumulative incidence rate of macrovascular events in the post-COVID-19 elderly cohort 13 weeks after discharge was 3.12%.

Elderly patients with a critical illness during hospitalization due to COVID-19 and elevated D-dimer values at discharge have the maximum risk of developing macrovascular thrombosis in the post-COVID-19 period. It is reasonable to recommend extended thromboprophylaxis for at least eight weeks in the post-COVID-19 elderly